equity investment

BioMérieux also has made a €9 million ($12.8 million) equity investment in Biocartis as part of the deal.

In June, Regulus announced that it had inked a deal giving Sanofi-Aventis the worldwide, exclusive rights to use its technology and know-how to discover, develop, and commercialize miRNA drugs, including a fibrosis treatment targeting miR-21.

The two companies will explore co-development opportunities combining PacBio's Single Molecule Real Time sequencer and Gen-Probe's diagnostics expertise.

Synthetic Genomics funded the work by Craig Venter that resulted in the first functional bacterial cells controlled by a synthetic genome.

GE will work with the molecular diagnostics startup on developing tests for cardiovascular diseases.

The transaction allows Novartis to maintain its roughly 13.4 percent equity stake in the RNAi drug developer.

The French diagnostics firm, which is targeting the development of sequencing-based diagnostics for cancer and infectious diseases, also has made a $5 million equity investment in Knome.

Under the amended deal, Benitec will no longer pay CSIRO royalties, while CSIRO gets a 10 percent stake in the company.

CVS Caremark is increasing its investment in Generation Health for an undisclosed amount. Additionally, the CEO of the genetic benefits management firm, Per Lofberg, will now take over as president of CVS Caremark's PBM division.

The firms are developing a test to differentiate schizophrenia from other psychiatric disorders.


Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.